Indonesia Next Generation Sequencing Market (2026-2036)
The Indonesia next generation sequencing market is expected to reach USD 275.39 million by 2036 from an estimated USD 75.60 million in 2026, at a CAGR of 13.8% during the forecast period from 2026 to 2036. The market was valued at USD 66.30 million in 2025.
- Published
- Sep 2026
- Pages
- 140
- Format
- PDF + Excel
- Report ID
- MR-2173
- Base year
- 2025
- 2025 · BASELINE
- $66.3M
- 2036
- $275.4M
- CAGR 2026–2036
- 13.8%
2025 baseline · 2026–2036 forecast at 13.8% CAGR · hover a bar for the value
Key highlights
The Indonesia next generation sequencing market is projected to reach USD 275.39 million by 2036 from an estimated USD 75.60 million in 2026, growing at a CAGR of 13.8% during the forecast period from 2026 to 2036.
The market was valued at USD 66.30 million in 2025, with government funded genomics programmes representing an important source of sequencing demand in the country.
The Biomedical and Genome Science Initiative has strengthened Indonesia's genomics infrastructure through the development of specialised genomics centres, national surveillance laboratories, and large scale whole genome sequencing programmes.
The Ministry of Health has set an objective of expanding human genome sequencing capacity substantially by 2030, creating continued demand for sequencing systems, consumables, sample preparation technologies, and bioinformatics solutions.
Indonesia's growing cancer burden is increasing the importance of molecular testing and genomic analysis. According to IARC estimates, the country recorded more than 400,000 new cancer cases in 2022, while the number of cases is expected to increase significantly in the coming years.
Government Regulation 28 of 2024 requires health data and health information systems to be stored and processed within Indonesian jurisdiction, supporting the development of domestic sequencing, data processing, and bioinformatics capabilities.
The sequencing segment is expected to hold the largest share of the Indonesia next generation sequencing market in 2026, supported by continued investment in sequencing infrastructure and the expansion of the national genomics programme.
Data analysis and bioinformatics is expected to register the fastest growth during the forecast period as the volume of genomic information generated in Indonesia continues to increase.
Research and other applications are expected to account for the largest share of the market in 2026, reflecting the strong role of government funded genomics and research programmes.
Hospitals, clinical and reference laboratories are expected to account for the largest share of the market among end users, supported by the expansion of sequencing capabilities within major healthcare institutions.
The market is consolidated and is led by international sequencing and life science companies, including MGI Tech Co., Ltd., Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., and BGI Genomics Co., Ltd.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026 to 2036 |
| Historical Year | 2024 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR | 13.8% |
| Format | PDF, Excel & Cloud Portal · 140 pages |
| Market Size in 2025 | USD 66.30 Million |
| Market Size in 2026 | USD 75.60 Million |
| Market Size in 2036 | USD 275.39 Million |
| Segments Covered | By Offering, Application, and End User |
| Country Covered | Indonesia |
| Key Companies | Illumina, Inc.; Thermo Fisher Scientific Inc.; QIAGEN N.V.; Agilent Technologies, Inc.; F. Hoffmann La Roche Ltd.; Revvity, Inc.; Pacific Biosciences of California, Inc.; Danaher Corporation; Oxford Nanopore Technologies plc; MGI Tech Co., Ltd.; BGI Genomics Co., Ltd.; Eurofins Scientific SE; Novogene Co., Ltd. |
Report overview
Segments covered: offering, application, end user.
Next generation sequencing comprises a group of high throughput technologies that determine the sequence of nucleotides across multiple DNA or RNA fragments simultaneously. The technology enables the analysis of targeted gene panels, whole exomes, and whole genomes and is increasingly used in clinical diagnostics, oncology, reproductive health, infectious disease surveillance, rare disease research, drug discovery, agriculture, and animal research. The Indonesia next generation sequencing market comprises revenues generated from sample preparation products, sequencing systems and consumables, data analysis and bioinformatics solutions, and commercial sequencing and outsourced services supplied to organizations operating within Indonesia.
Indonesia's genomics ecosystem is undergoing significant development through government investment in population genomics and precision medicine infrastructure. The national genomics programme has expanded the country's sequencing capacity from approximately 12 machines to around 60 machines. The Ministry of Health has also added 48 whole genome sequencing machines across national referral hospitals, significantly expanding the country's domestic sequencing infrastructure. The expansion of infrastructure is being supported by a network of hospitals and specialised genomics facilities. Ten Ministry of Health vertical hospitals coordinate the national genomics programme, while ten specialised genomics centres operate across the country. In addition, the laboratory network equipped with support from the United Nations Development Programme extends to 29 established laboratories. This growing infrastructure base is increasing demand for sequencing consumables, laboratory support services, data management systems, and bioinformatics capabilities. Indonesia's large and genetically diverse population also creates substantial opportunities for population specific genomic research. The development of domestic genomic databases can improve the interpretation of genetic variants and support precision medicine approaches designed around the characteristics of Indonesian populations.
Government requirements related to health data processing are also influencing the development of the market. The requirement that health data be processed within Indonesian jurisdiction is encouraging healthcare organizations and sequencing providers to develop domestic sequencing, data storage, and bioinformatics capabilities. This is expected to gradually reduce dependence on overseas facilities for selected genomic workflows and create opportunities for local infrastructure and service providers.
Market dynamics
9 factors across 3 forcesScale and Continuity of the National Genomics Programme
The continued expansion of Indonesia's national genomics programme is one of the most important factors supporting the growth of the next generation sequencing market. Government investment has substantially increased the country's sequencing infrastructure, with the installed base expanding from approximately 12 sequencing machines to around 60 machines.
The Ministry of Health has added 48 whole genome sequencing machines across national referral hospitals and has established a network involving ten Ministry of Health vertical hospitals and ten specialised genomics centres. The programme is also supported by a broader laboratory network extending to 29 established laboratories. These investments are creating sustained demand not only for sequencing systems but also for proprietary consumables, sample preparation technologies, automation platforms, software, and genomic data analysis services.
The national programme is expected to remain an important source of demand because large scale population genomics requires continued sequencing activity rather than a one time investment in instruments. The Ministry of Health has set an objective of sequencing 400,000 human genomes by 2030, indicating the scale of sequencing activity that could be required as the programme continues to expand.
Rising Cancer Burden and Growing Demand for Molecular Testing
The growing burden of cancer is increasing the importance of molecular diagnostics and genomic testing in Indonesia. Cancer patients increasingly require technologies that can identify genetic alterations and support treatment selection, particularly as precision oncology becomes more important in clinical practice.
Next generation sequencing can support the identification of actionable mutations, tumour profiling, hereditary cancer risk assessment, and the development of more personalized treatment approaches. The continued expansion of oncology applications is therefore expected to create demand for sequencing systems, targeted sequencing panels, consumables, and specialised bioinformatics services.
Within the Indonesia NGS market, oncology is expected to register the highest growth among major clinical applications, with a CAGR of 14.8% during the forecast period. This reflects the growing clinical importance of genomic testing, although the expansion of the segment continues to be influenced by the limited inclusion of genomic diagnostics within the national insurance benefit package.
Exceptional Genetic Diversity of the Indonesian Population
Indonesia's large and genetically diverse population provides an important foundation for population genomics and genomic research. Population specific genomic information can improve the interpretation of genetic variants and support the development of more relevant diagnostic and precision medicine applications.
The continued development of national genomic databases is expected to create opportunities across population research, rare disease analysis, pharmacogenomics, and clinical diagnostics. As more genomic information is generated, Indonesia will also require greater capacity for storing, processing, interpreting, and managing complex genomic datasets.
Table of contents
10 chapters · 186 sections · 140 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Offering | Sequencing | While Data Analysis and Bioinformatics |
| By Application | Research and Other | — |
| By End User | Hospitals, Clinical and Reference Laboratories | — |
By Offering
- Sequencing Segment to Hold the Largest Share in 2026, While Data Analysis and Bioinformatics Registers the Fastest Growth
- The sequencing segment is expected to account for the largest share of the market in 2026, supported by continued investment in sequencing infrastructure and the expansion of the national genomics programme.
- The growing installed base of sequencing systems is also generating recurring demand for proprietary consumables and related services.
- The data analysis and bioinformatics segment is expected to register the highest growth during the forecast period as the volume of genomic data generated in Indonesia continues to increase and healthcare and research organizations strengthen their capacity for genomic data processing and interpretation.
By Application
- Research and other applications are expected to account for the largest share of the market in 2026.
- The strong position of this segment reflects the role of government funded genomics programmes and public research initiatives in generating sequencing demand.
- Clinical applications are expected to continue expanding as next generation sequencing gains importance in oncology, reproductive health, infectious diseases, rare diseases, and other areas of precision medicine.
By End User
- Hospitals, clinical and reference laboratories are expected to account for the largest share of the market in 2026.
- The expansion of sequencing capacity within major healthcare institutions and the role of hospitals in delivering national genomics programmes are supporting the growth of this segment.
- Academic and research institutes also represent an important source of demand, while pharmaceutical and biotechnology companies are expected to increase their use of sequencing technologies for drug discovery, biomarker research, and precision medicine.
Competitive landscape
The Indonesia next generation sequencing market is consolidated and is led primarily by international technology and life science companies. Major companies operating in the market include MGI Tech Co., Ltd., Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., and BGI Genomics Co., Ltd.
Other prominent companies operating in the market include Agilent Technologies, Inc., F. Hoffmann La Roche Ltd., Revvity, Inc., Pacific Biosciences of California, Inc., Danaher Corporation, Oxford Nanopore Technologies plc, Eurofins Scientific SE, and Novogene Co., Ltd. The competitive landscape is being shaped by government procurement, the expansion of national genomics infrastructure, local distribution partnerships, product launches, acquisitions, collaborations, and the development of integrated sequencing workflows. The selection of sequencing technology for large scale national programmes can have a significant influence on the installed base and long term demand for consumables, automation systems, and related technologies.
- —
MGI Tech strengthened its genomics capabilities through strategic developments that expanded its presence across sequencing and related genomic technologies.
- —
Illumina continued to strengthen its broader genomics portfolio through acquisitions and technology development, supporting its position across sequencing and multiomics applications.
- —
Thermo Fisher Scientific continued to expand its life science and proteomics capabilities through strategic acquisitions and investments.
- —
QIAGEN strengthened its genomics and sample analysis capabilities through portfolio expansion and strategic developments.
- —
Leading sequencing companies continue to focus on integrated workflows combining sample preparation, automation, sequencing, and data analysis to strengthen their positions in the Indonesian market.
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Agilent Technologies, Inc.
- F. Hoffmann La Roche Ltd.
- Revvity, Inc.
- Pacific Biosciences of California, Inc.
- Danaher Corporation
- Oxford Nanopore Technologies plc
- MGI Tech Co., Ltd.
- BGI Genomics Co., Ltd.
- Eurofins Scientific SE
- Novogene Co., Ltd
Frequently asked questions
The Indonesia next generation sequencing market is estimated at USD 75.60 million in 2026.
Cite this report
Meticulous Research. (2026). Indonesia Next Generation Sequencing Market - Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-2173). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/indonesia-next-generation-sequencing-market-6856